Today’s AI Top Pick: TMDX

7/23/2026 · Highly Shorted High Growth Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live TMDX price forecast →

Today's pick · Highly Shorted High Growth Deep RotationTMDXBUY NOW8.4 / 107/23/2026

TransMedics (TMDX) is the cleanest risk/reward on the board today. It clears the screen decisively (shortFloat 23.68%, epsNextY 70.61%, salesYoY 30.24%) and pairs those with real, GAAP-positive fundamentals that most peers on this list simply don't have: PE 16.34, ROE 45.22%, operating margin 14.85%, profit margin 27.04%. Analyst support is strong (recom 1.64, targetUpsidePct 60.1%) and the fundamental_score of 6.75 is among the best in the pool. Unlike CELH (fund_score 8 but near_term_bullish only 0.2 and pinned at 100% of the 1h range) or PGY (fund_score 8 but the tape says otherwise — 1h/4h/wk forecasts are all negative, weekly fc_long -48%), TMDX's fundamentals and forecast tape actually agree. Multi-timeframe forecast alignment is strong on the horizons that matter for a swing entry. Daily forecasts are the standout: fc_short +53.79%, fc_mid +60.13%, fc_long +57.57%, with bullish_prob 1.0. The 4h confirms (+46.12 / +47.54 / +33.09) and the weekly, while noisy near-term, still ends with fc_long +19.28%. The only weak spot is the 1h fc_short at -3.11% — a modest dip that actually helps the entry rather than hurts the thesis. Critically, price is NOT extended. The stock sits at $72 with a weekly drawdown of -44.45% from the 21-bar high and pos_in_21bar_range_pct of just 13.25% on the weekly and 49.25% on the daily — i.e., you're buying mid-range on the daily after a deep multi-month washout, not chasing a breakout. That's exactly the 'deep rotation' setup this lens is designed to catch. Recent news (Evercore lowered PT to $90 but maintained Outperform) is a mild negative already reflected in the -41.47% YTD drawdown; the analyst is still bullish just at a lower target that still implies 25%+ upside. Why today, not later: near_term_bullish is 0.6 with the 4h and 1d forecasts firing in unison, the 1h is slightly dipped (better fill) and Kronos bullish_prob is a full 1.0. Waiting risks missing the 4h fc_short move (+46% projected). CRK is a close #2 with better near-term momentum but weaker analyst backing (recom 2.76, target upside only 19.8%) and a looming earnings-decline print — the setup is good but the catalyst window is riskier.

TMDX forecast chart
Entry zone
$70.50–$72.50 (buy at market or on any dip to the $70 handle; 1h fc_short -3.11% suggests a small pullback is plausible into entry)
Stop loss
$64.50 (below recent swing low and roughly -10%; invalidates the mid-range reclaim)
First target
$85–$88 (aligns with 4h fc_short +46% pathing and prior daily supply)
Longer target
$105–$115 (tracks 1d fc_mid +60% / fc_long +57% and Evercore's $90 PT gives way to consensus higher targets if execution holds)
Risks
  • Recent analyst PT cuts (Evercore to $90) signal Street is trimming expectations — a soft print could trigger another leg down
  • Short float 23.68% cuts both ways — supportive on a squeeze, punishing on bad news
  • Weekly drawdown of -44.45% shows the trend is still repairing; a break of $64.50 opens the door to retest lows
  • PE 16.34 vs fwdPe 23.14 implies forward earnings deceleration relative to trailing — needs to be watched on the next report
  • Debt/Equity 1.75 is elevated for a medtech; rate/refi shock would compress the multiple
Honorable mentions
CRKCheapest name in the pool (PE 6.63, PEG 0.5), profit margin 30.99%, near_term_bullish 1.0, all four TFs positive on short/mid horizons (1d fc +28/+44/+40). Held back only by recom 2.76, targetUpsidePct just 19.8%, and Zacks flagging an expected earnings decline — the tape is great, the fundamental catalyst is weaker.
MNDYBest forecast magnitude in the pool: 1d fc_mid +67%, fc_long +75%; 1wk fc_mid +127%, fc_long +180%. PEG 1.12, fwdPe 13.3, gross margin 89%. Fresh 20% layoff / AI-restructure headline is a coin flip — market may take it as bullish, but execution risk is real, so it's #3 not #1.
Full ranking (30)
#SymbolVerdictScoreRead
1TMDXBUY NOW8.4Screen winner with real profits — daily fc +54/+60/+58%, mid-range entry after -44% weekly drawdown, analyst rec 1.64.
2CRKBUY NOW8.1Cheapest, most profitable name here (PE 6.63, margin 31%) with all short-term TFs green and 29% short float for squeeze fuel.
3MNDYBUY PULLBACK7.6Massive forecast magnitudes (1wk fc_long +180%) but 1h at 100% of range and layoff headline needs to digest.
4FOURBUY PULLBACK7.2fwdPe 7.1, 1d fc +38/+27/+20 and weekly +33/+46/+47, but 4h/1h short-term forecasts are negative — wait for dip.
5CELHBUY PULLBACK6.9Fund_score 8, sales +123%, but pinned at 100% of 1h range and near_term_bullish only 0.2 — chase risk.
6UPSTBUY NOW6.71d fc +24/+49/+38, weekly +31/+28/+33, pos_in_range 0% on daily — bombed-out entry with 32% short float.
7KVYOBUY PULLBACK6.31d fc +24/+30/+38, near_term_bullish 0.8, gross margin 74.5%, but 1h fc_short negative.
8TTANWAIT5.9Daily fc +11/+30/+12 decent but 1h/4h forecasts are negative and no bullish_prob signal available.
9BRZEWAIT5.7Solid analyst rec (1.09) and JPM/Goldman positive, but bullish_prob 0 and forecast magnitudes muted.
10DUOLWAIT5.6ROE 37%, margin 38%, 1d fc_mid +36/+45 but targetUpsidePct is NEGATIVE -5.4% and 1h/4h fc are down.
11PDYNBUY PULLBACK5.5USAF contract catalyst + 1d fc +35/+36/+33, but 1wk fc all negative and PS 35.6 is stretched.
12ASSTWAIT5.4Strong 1d fc +36/+29/+64 but pos_in_range 79% (near top) and PS 184 is absurd; Bitcoin narrative-driven.
13MPBUY PULLBACK5.2Rare-earth catalyst tailwind, 1h fc +30% and near_term_bullish 0.8, but weekly fc_long -41% and Needham cut PT.
14BTDRWAIT5.0June Bitcoin production +388% Y/Y is strong but 1wk fc_long -24.5% and bullish_prob only 0.6.
15QXOBUY PULLBACK4.9Massive forecast tailwind (1d fc +28/+46/+39) and Jacobs playbook, but near_term_bullish 0 and pos_in_range 0% weekly (falling knife).
16ZENAWAIT4.8Defense drone catalysts + 1d fc +75/+119/+152, but micro-cap with -134% ROE and PS 9 — pure speculation.
17SAILWAIT4.61d fc +22/+32/+30 decent but 1h fc negative, at 100% of 1h range, no bullish_prob signal.
18KLARBUY PULLBACK4.5Apple leasing catalyst drove +9% pop, epsNextY +292%, but 1h fc -12% suggests digestion needed.
19ABATWAIT4.3DOE grant reinstated + near_term_bullish 1.0, but op margin -390% and 1wk fc_short still -3%.
20BIRKAVOID4.0Seaport downgrade, all forecasts negative or flat, bullish_prob 0.2 — thesis broken.
21RDWWAIT3.9Space narrative alive but profit margin -93% and mixed forecasts, and flagged as 'risky' by StockStory.
22KULRWAIT3.8Icarus contract win but 1d fc -6/-15/+9 negative and pos_in_range 22% with profit margin -384%.
23ASPIWAIT3.7Noble Africa listing catalyst but 1d fc not shown positively enough vs risk; sales +511% is base-effect.
24VIAAVOID3.51h/4h/1d forecasts all mostly negative, no bullish_prob, no near-term signal.
25COSMAVOID3.3Weekly fc_long -88.6%, sub-$1 penny stock with -30% profit margin — buyback narrative not enough.
26INVAVOID3.2PS 86.6, op margin -3586%, profit margin -5226% — a fundamentals catastrophe.
27PROPAVOID3.0Debt/Equity 1222, ROE -700%, 1wk fc_short -55.9% — leverage disaster despite the sales-growth number.
28TNXPAVOID2.9Only 1d TF available, near_term_bullish 0, op margin -861%, profit margin -839%.
29PGYAVOID2.6Fund_score 8 but 1h/4h/1wk forecasts are all negative — weekly fc_long -48% completely breaks the thesis.
30ADTNAVOID2.0Q2 revenue guidance CUT on 7/22; bullish_prob 0 and 1d fc negative — landmine confirmed.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.